Bedrosian Camille L's Form 4 filing
Amylyx Pharmaceuticals, Inc. (AMLX) · filed Oct 2, 2024
- Accession no.
- 0000950170-24-111809
- Filed
- Oct 2, 2024
- Trade date
- Sep 30, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $36.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bedrosian Camille LCIK 0001326969 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 30, 2024 | Common Stock | SSaleDisposed | −11,442 | $3.20 | −$36,614.4 | 143,801 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.